Adhoc: BioVersys AG: First ever Patient dosed with alpibectir-ethionamide in combination with first-line TB drug in a 14-day Phase 2 clinical trial
BioVersys AG / Key word(s): Miscellaneous FIRST EVER PATIENT DOSED WITH ALPIBECTIR-ETHIONAMIDE IN COMBINATION WITH FIRST-LINE TB DRUGS IN A 14-DAY PHASE 2 CLINICAL TRIAL 19-March-2025 / 07:00 CET/…